NEW YORK, Feb. 10, 2022 /PRNewswire/ -- The global Cancer and Tumor Profiling market size is expected to reach USD 18.13 Billion in 2028 and register a revenue CAGR of 10.3% over the forecast period, according to latest report by Reports and Data. Rising prevalence of various cancer types across the globe is one of the major factors driving Cancer and Tumor Profiling market revenue growth. Governments of various countries worldwide are funding in technological developments for more advanced drugs and therapies to treat cancer. Additionally, rising awareness among people about importance of cancer detection at an early stage is driving demand for cancer profiling.
At present, cancer patients are usually prescribed with one or more treatment processes, such as surgery with chemotherapy or radiation therapy. These therapies are known to have several side effects. However, scientists have discovered ways of reducing side effects of such therapies by focusing on targeted treatment, a treatment involving attack on cancer cells only and preventing healthy cells from getting damaged. Cancer or tumor profiling is mandatory for proper use of targeted medicine to understand drug effectiveness for a particular type of cancer. This, in turn, is creating higher demand for Cancer and Tumor Profiling among oncologists.
According to WHO, in 2020, there was an estimated rise in cancer cases by 19.3 Million, with 10 Million deaths worldwide. Among these new cases, breast and lung cancer accounted for 23.1% of all cancer cases. Rising number of cancer cases is invoking various major players to investment in development of innovative and more advanced technologies for cancer profiling, such as Chromogenic In Situ Hybridization (CISH). CISH has been designed specifically for detecting HER-2/neu oncogene amplification, and this gene confirms presence or absence of breast cancer. However, for chromosomal abnormalities, Fluorescence In Situ Hybridization (FISH) is considered as ideal option due to its accuracy and high resolution.
Request a Sample Report – https://www.reportsanddata.com/sample-enquiry-form/4839
Some Key Highlights from the Report
- Blood samples can detect cell-free DNA, circulating tumor cells, and exosomes, as well as macrovesicles. Inspite of having various pre-existing applications and purification processes, blood sampling is most commonly used for liquid biopsy studies and product innovations.
- Immunohistochemistry (IHC) technology is widely accepted by laboratories to detect protein biomarkers in several types of cancers. Using mass spectrometry, this technology will be upgraded for detecting presence, abundance, location, and functional state of up to 100 targets.
Ask for Customize Research Report @ https://www.reportsanddata.com/request-customization-form/4839
- In November 2021, Illumina and Sequoia Capital China jointly announced funding two startup companies poised to deliver breakthrough applications in genomics and multiomics. One startup company focuses on cutting-edge, single-cell sequencing technologies for molecular diagnostics applications, whereas the other is committed to building DNA, RNA epitome, and proteomics technology platforms for research and clinical applications.
- As per WHO reports, there has been significant rise in cancer mortality cases in Africa and Asia due to inadequate number of specialized cancer hospitals, diagnostic centers, and institutes.
- Companies profiled in the global market report include Thermo Fisher Scientific Inc., Illumina Inc., Siemens AG, F.Hoffmann La Roche Ltd, Nanostring Technologies Inc., BioGenex, NeoGenomics Laboratories Inc., HTG Molecular Diagnostics Inc., Perkin Elmer Inc., CellCarta Inc., Ribomed Biotechnologies Inc., Perthera, Qiagen N.V., and Personalis Inc.
To identify the key trends in the industry, research study at https://www.reportsanddata.com/report-detail/cancer-and-tumor-profiling-market
For this report, Reports and Data has segmented the global Cancer and Tumor Profiling market based on cancer type, technology, biomarker type, process type, application, and region:
- Cancer Type Outlook (Revenue, USD Billion; 2018–2028)
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Melanoma
- Ovarian Cancer
- Stomach Cancer
- Pancreatic Cancer
- Thyroid Cancer
- Sarcoid
- Other
- Technology Outlook (Revenue, USD Billion; 2018–2028)
- Immunohistochemistry(IHC)
- Fluorescence in situ Hybridization (FISH)
- Next-Generation Sequencing (NGS)
- Quantitative Polymerase Chain Reaction (qPCR)
- Chromogenic in Situ Hybridization (CISH)
- Microarray
- Others
- Biomarker Type Outlook (Revenue, USD Billion; 2018–2028)
- Genetic
- Protein
- Others
- Process Type Outlook (Revenue, USD Billion; 2018–2028)
- Genomics
- Proteomics
- Epigenetics
- Metabolomics
- Others
- Application Outlook (Revenue, USD Billion; 2018–2028)
- Research
- Clinical
- Machine learning
Buy Premium Research Report @ https://www.reportsanddata.com/checkout-form/4839
- Regional Outlook (Revenue, USD Billion; 2018–2028)
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Sweden
- BENELUX
- Rest of Europe
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Rest of LATAM
- Middle East & Africa
- Saudi Arabia
- UAE
- South Africa
- Israel
- Rest of MEA
Explore Trending Research Reports by Reports and Data:
Membrane chromatography market size was USD 198.51 Million in 2020 and is expected to register a CAGR of 15.8% during the forecast period. Increasing advantages of membrane chromatography over conventional chromatography techniques, rising investment in R&D activities in the biopharmaceutical sector, and rapid advancements in downstream purification processes are key factors expected to drive market revenue growth.
Protein crystallization & crystallography market size was USD 1.10 Billion in 2020 and is expected to register a CAGR of 9.2% during the forecast period. Increasing application of protein crystallization for elucidating membrane protein structure, continuous investments in research and development and on technological advancements, and rising adoption of protein therapeutics are some major factors expected to continue to drive market revenue growth.
Spatial genomics & transcriptomics market size was USD 178.4 Million in 2020 and is expected to register a CAGR of 18.1% during the forecast period. Increasing application of spatial genomics and transcriptomics in identification of biomarkers and in drug discovery, technological advancements in sequencing technologies, and significant funding to expand research and development activities in spatial-based technology are key factors expected to drive market revenue growth
Compound management market size was USD 353.8 million in 2020 and is expected to register a CAGR of 17% during the forecast period. Steady market revenue growth is primarily attributed to rapidly expanding pharmaceutical and biotechnology industries, rise in drug discovery & development activities, surging demand for compound management outsourcing services, and increasing activities of sample collection, storage, and transportation.
Rheometers and viscometers market size was USD 791.62 million in 2020 and is expected to register a CAGR of 4.3% during the forecast period. Steady market revenue growth is driven by increasing demand for advanced rheometers and viscometers across a wide range end-use industries including biotechnology and pharmaceutical, petrochemical refineries, cosmetics and food & beverage industries, and from chemical and material manufacturers.
About Reports and Data
Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.
Contact:
John W
Head of Business Development
Reports And Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370
E-mail: sales@reportsanddata.com
LinkedIn | Twitter | Blogs
Read Latest Press Release @ https://www.reportsanddata.com/press-release/global-cancer-and-tumor-profiling-market
Logo: https://mma.prnewswire.com/media/1009077/Reports_And_Data_Logo.jpg
Share this article